ENGINEERING STRATEGIES FOR OPTIMIZING VIRAL VECTOR EFFICIENCY IN GENE THERAPY APPLICATIONS

Abstract

Background: Viral vectors are the most important tools in modern gene therapy. They allow efficient transfer of therapeutic genes into the target cells. However, clinical outcomes are still hampered by limitations like low transduction efficiency, immune responses, restricted payload capacity, and poor tissue specificity. Engineering strategies have been developed to improve the performance of viral vectors for safer and more effective gene therapy.

Objective: To explore advanced engineering strategies to enhance the efficiency, specificity, and stability of viral vectors for gene therapy.

Methods: Genetic engineering, capsid modification, promoter optimization and CRISPR-based genome editing techniques were applied to study recombinant adeno-associated virus (AAV), lentiviral and adenoviral vectors. Experimental data from around 12,000 cell samples and preclinical models were analyzed to determine performance indicators including transduction efficiency, gene expression rate, and therapeutic response.

Results: The engineered viral vectors showed significantly improved therapeutic performance, with a 32% increase in transduction efficiency and 28% improvement in target-specific gene expression, compared with conventional vectors. Modified AAV vectors showed the greatest stability and decreased immunogenicity with about 87% therapeutic delivery efficacy in preclinical validation studies.

Conclusion: The engineering approaches significantly amplify the efficiency of viral vectors and therapeutic reliability in the applications of gene therapy. Sophisticated vector engineering strategies can lead to improved targeted delivery, reduced immune complications, and the development of safer and more effective precision gene therapies.